184 related articles for article (PubMed ID: 37278880)
21. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
Regazzi M; Carvalho AC; Villani P; Matteelli A
Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
[TBL] [Abstract][Full Text] [Related]
22. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
23. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
[TBL] [Abstract][Full Text] [Related]
25. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
[TBL] [Abstract][Full Text] [Related]
26. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
Krishna R; East L; Larson P; Siringhaus T; Herpok L; Bethel-Brown C; Manthos H; Brejda J; Gartner M
Biopharm Drug Dispos; 2016 Dec; 37(9):542-549. PubMed ID: 27704562
[TBL] [Abstract][Full Text] [Related]
27. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
28. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver.
Oesch F; Arand M; Benedetti MS; Castelli MG; Dostert P
J Antimicrob Chemother; 1996 Jun; 37(6):1111-9. PubMed ID: 8836814
[TBL] [Abstract][Full Text] [Related]
29. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
30. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study.
Hee KH; Yao Z; Lee LS
J Pharm Biomed Anal; 2014 Jan; 88():584-93. PubMed ID: 24211708
[TBL] [Abstract][Full Text] [Related]
32. A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.
Tariq B; Conto S; Cohen A; Sahasranaman S; Ou YC
Clin Pharmacol Drug Dev; 2023 Aug; 12(8):832-838. PubMed ID: 37145975
[TBL] [Abstract][Full Text] [Related]
33. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
Ji T; Chen X; Yeleswaram S
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
[TBL] [Abstract][Full Text] [Related]
35. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
[TBL] [Abstract][Full Text] [Related]
36. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
37. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
38. Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Djebli N; Buchheit V; Parrott N; Guerini E; Cleary Y; Fowler S; Frey N; Yu L; Mercier F; Phipps A; Meneses-Lorente G
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):779-791. PubMed ID: 34495458
[TBL] [Abstract][Full Text] [Related]
39. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
40. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
